The ADVANCE Trial: Clarifying the Role of Perindopril/Indapamide Fixed-Dose Combination in the Reduction of Cardiovascular and Renal Events in Patients with Diabetes Mellitus. American journal of cardiovascular drugs : drugs, devices, and other interventions [Am J Cardiovasc Drugs] Journal article | | Title | The ADVANCE Trial: Clarifying the Role of Perindopril/Indapamide Fixed-Dose Combination in the Reduction of Cardiovascular and Renal Events in Patients with Diabetes Mellitus. | | Author(s) | Waeber B, de la Sierra A, Ruilope LM | | Institution | Division of Clinical Pathophysiology, University Hospital and University of Lausanne, Lausanne, Switzerland. | | Source | Am J Cardiovasc Drugs 2009; 9(5):283-91. | | Abstract | Patients with type 2 diabetes mellitus exhibit a marked increase in cardiovascular and renal risk. A number of interventional trials have shown that these patients benefit greatly from aggressive BP lowering, especially when the drug regimen comprises an inhibitor of the renin-angiotensin system. The results of the placebo-controlled ADVANCE (Action in Diabetes and Vascular disease: PreterAx and DiamicroN MR Controlled Evaluation) trial, conducted in patients with type 2 diabetes, are exemplary in this respect. The systematic use of a fixed-dose combination containing the ACE inhibitor perindopril and the diuretic indapamide afforded substantial protection against cardiovascular mortality and myocardial infarction, while providing important renoprotection, reducing the development of micro- and macroalbuminuria, and allowing regression of nephropathy. The beneficial effects were obtained regardless of baseline BP and whether or not the patients were receiving antihypertensive therapy. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19791837 |
|
|
| |
Advertise on this site.
| | |
|
